Hangzhou Tigermed Consulting Co Ltd operates in the Medical laboratories sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Hangzhou Tigermed Consulting Co Ltd with three other
pharmaceutical manufacturers in Asia:
Dr. Lal PathLabs Ltd
sales of 10.57 billion Indian Rupees [US$148.07 million]
of which 100%
Falco Holdings Co Ltd
(45.96 billion Japanese Yen [US$422.39 million]
of which 60%
was Medical Test), and
Prodia Widyahusada Tbk PT
based in Indonesia
(1.60 trillion Indonesian Rupiahs [US$112.94 million]
Hangzhou Tigermed Consulting Co Ltd reported sales of 2.30 billion Chinese Renmimbi (US$324.30 million)
December of 2018.
increase of 36.4%
versus 2017, when the company's sales were 1.69 billion Chinese Renmimbi.
Sales at Hangzhou Tigermed Consulting Co Ltd have increased during each of the previous five years
(and since 2013, sales have increased a total of 584%).
Sales of Service saw an increase
39.6% in 2018, from
1.65 billion Chinese Renmimbi to 2.30 billion Chinese Renmimbi.
Not all segments of Hangzhou Tigermed Consulting Co Ltd experienced an increase in sales in 2018:
sales of Other fell 93.5% to 2.63 million Chinese Renmimbi.
(However, this segment's sales were only a very small portion of the company's overall sales).